Turn Biotechnologies has acquired the ARRDC1 Mediated Microvesicles (ARMMs) technology platform from Harvard University, significantly enhancing its capabilities in epigenetic reprogramming.

This ARMMs technology utilizes human extracellular vesicles to efficiently transport therapeutic agents between cells, which minimizes unintended effects and addresses a major challenge in gene therapy.

Turn Bio's eTurna lipid nanoparticle system complements this by ensuring clinical safety while maintaining efficacy, allowing for the delivery of therapeutic agents to multiple targets in the body.

CEO Anja Krammer emphasized that combining ARMMs with eTurna will enhance delivery capabilities for gene editors, proteins, and RNA-based therapies, overcoming traditional delivery limitations.

Preclinical data indicate that ARMMs technology effectively delivers therapies to various tissues, including the retina and lungs, and is expected to accelerate drug development, particularly in ophthalmology and immune cell rejuvenation.

Turn Bio is preparing for an Investigational New Drug (IND) application, having demonstrated proof of concept in primates and other animal models.

Previously, Turn Bio secured a global licensing agreement worth up to $300 million with HanAll Biopharma to develop treatments for age-related eye and ear conditions.

The core technology of Turn Bio focuses on restoring the epigenome to a youthful state, potentially addressing issues such as skin aging, vision deterioration, muscle loss, and joint degeneration.

The company aims to enter clinical trials for its skin rejuvenation program by 2026, following its IND-enabling studies and ongoing Series B fundraising efforts.

This technology aims to improve the targeting of various tissues and organs, thereby increasing the precision and effectiveness of Turn Bio's therapies for age-related conditions.